Haemadipsa sylvestris antithrombotic peptide sylvestin and use thereof
AssigneesKunming Institute of Zoology, Chinese Academy of Sciences, Kunming Longjin Pharmaceutical Co., Ltd.
InventorsRen Lai, Weihui Liu, Chengbo Long, Qiumin Lv
Life of this patent
Estimating the term…
Abstract
Provided are a Haemadipsa sylvestris antithrombotic peptide Sylvestin and the use thereof, falling within the technical field of biomedicine. The Haemadipsa sylvestris antithrombotic peptide sylvestin can inhibit FXIIa and kallikrein, has anti-thrombus/infarction effects and alleviates injuries caused by cerebral ischemia, and can also be used in the preparation of inhibitors of FXIIa and kallikrein and drugs for anti-thrombus/infarction and anti-cerebral ischemic injuries.
Claims8
A polypeptide having anti-thrombus activity, which is derived from Haemadipsa sylvestris antithrombotic peptide Sylvestin, comprising
- (1) a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO:
- 1, or
- (2) a sequence obtained by adding, deleting, or replacing one or more amino acids in the amino acid sequence set forth in SEQ ID NO:
- 1.
-7. (canceled)
Dependencies are inferred from the claim text.